Jcog9511
Web1 gen 2014 · The doses of cisplatin were the same as in the previous JCOG trial (JCOG9511) in extensive-stage SCLC. 9 If the leucocyte count decreased to less than 3000 leucocytes per μL or the platelet count fell below 10 5 platelets per μL on the first day of etoposide plus cisplatin or irinotecan plus cisplatin, chemotherapy was withheld until the … WebJCOG9511 (phaseIII) 進展型小細胞肺癌（ED-SCLC）に対する塩酸イリノテカン＋シスプラチンとエトポシド＋シスプラチンの第Ⅲ相無作為化比較試験 研究グループ
Jcog9511
Did you know?
http://www.jcog.jp/document/9511.htm http://www.jcog.jp/document/9511.htm
WebWe thank Nobuyuki Horita and colleagues for their interest in the updated results of the CASPIAN trial.1 We believe that the platinum–etoposide chemotherapy regimen used in CASPIAN was appropriate. Major oncological treatment guidelines worldwide recommend either cisplatin or carboplatin, combined with etoposide, as the standard first-line … WebView the manual for the Canon PIXMA G4511 here, for free. This manual comes under the category Printers and has been rated by 16 people with an average of a 8.8. This manual is available in the following languages: English. Do you have a question about the Canon PIXMA G4511 or do you need help?
Web3 nov 2012 · In the JCOG9511 study , grade 3 to 4 diarrhea occurred in 16.0 % of patients treated with cisplatin plus CPT, whereas there was 8.0 % in the present study. Two patients who developed grade 3 diarrhea were switched to the cisplatin plus etoposide regimen and were able to receive a total of 4 cycles of first-line chemotherapy. Web1 mag 2002 · In the past decade, the quality of Japanese clinical studies has improved tremendously. The results of JCOG9511 have recently been reported; and demonstrated that treatment with irinotecan/cisplatin significantly improved patient survival in extensive-stage small-cell lung cancer over standard etoposide/cisplatin, with less myelosuppression.
Web28 giu 2014 · In terms of treatment for extensive-stage SCLC, IP demonstrated superiority to EP in a randomized controlled trial conducted in Japan (JCOG9511). 17 IP is still considered a standard therapy for extensive-stage SCLC in Japan, although two subsequent randomized controlled trials conducted outside Japan were not able to confirm these …
Web3 dic 2013 · (JCOG9511) comparing irinotecan plus cisplatin versus etoposide plus cisplatin for extensive-stage SCLC. Median overall survival was 12·8 months and 19·5% patients were alive at 2 years in the irinotecan plus cisplatin group, whereas in the etoposide plus cisplatin group, median overall survival was 9·4 months only 5·2% of patients were alive … treku lauki tv cabinet[email protected] 1 Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-sayama, Osaka 589-8511, Japan 2 Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan trela buskoWeb13 dic 2013 · In contrast, the dose intensity of irinotecan (60 mg/m 2, Days 1, 8 and 15, every 4 weeks) was 45 mg/m 2 /week in JCOG9511. However, the omission of Day 15 irinotecan occurred in 50% of the courses in JCOG9511 . treku zaragozaWeb3 dic 2013 · (JCOG9511) comparing irinotecan plus cisplatin versus etoposide plus cisplatin for extensive-stage SCLC. Median overall survival was 12·8 months and 19·5% patients were alive at 2 years in the irinotecan plus cisplatin group, whereas in the etoposide plus cisplatin group, median overall survival was 9·4 months only 5·2% of patients were alive … treku mobiliarioWeb2 mar 2024 · We read with great interest the Article by Jonathan Goldman and colleagues1 regarding the updated data from the CASPIAN trial. The combination of a PD-L1 inhibitor plus platinum–etoposide has been suggested for the first-line treatment of extensive-disease small-cell lung cancer.1,2 However, we have a concern about the standard regimen of … trela komornikWebThe New England Journal of Medicine: Research & Review Articles on ... trela janosikWeb10 ago 2024 · JCOG previously reported the results of a randomized phase III trial (JCOG9511). They found that irinotecan, an inhibitor of the nuclear enzyme topoisomerase I, could improve OS and PFS when combined with platinum. Nevertheless, a series of studies conducted in America and Europe failed to confirm these positive results … trelast i oslo